Kyorin

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
NRP2, Research, Safety, SAN, Neuropilin, PST, D, BLA, Sarcoidosis, ILD, Scleroderma, International, Investment, Systemic scleroderma, ERS, Clinical trial, Patient, European Respiratory Society, DSMB, Rheumatoid arthritis, ATyr Pharma, American College, American College of Rheumatology, Small RNA, The Journal, Frontiers, Skin, ACR, Poster, Biologics license application, Pharmaceutical industry, Pharmacology, Kyorin

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.

Key Points: 
  • Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments.
  • SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company expects to complete enrollment in the study early in the second quarter of 2024.
  • G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2023.

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 9, 2023
Transforming growth factor beta, EST, Medicine, IND, ATyr Pharma, Kyorin, European Medicines Agency, Conference, Clinical trial, Sarcoidosis, ILD, DC, Diagnosis, Interest, Food and Drug Administration, Systemic scleroderma, SAN, Committee, D, EMA, Fibrosis, Patient, FDA, Research, PST, Investigational New Drug, European Patent Office, Disease, American Thoracic Society, Food, Small RNA, European Patent Convention, Patent, Civil service commission, ATS, European Commission, Exercise, Investment, DARS, Scleroderma, Tokyo International Conference on African Development, Safety, Pharmaceutical industry, LTBP1, EU

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.
  • This achievement triggered a $10.0 million milestone payment to aTyr in the fourth quarter.
  • Based on the Company’s current operational plans and existing cash, aTyr believes the Company’s cash runway will extend into 2026.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd.

Retrieved on: 
Monday, February 6, 2023
Disease, Food, Food and Drug Administration, Safety, RNA transfection, ATyr Pharma, Inflammation, Neuropilin, NRP2, ILD, Interstitial lung disease, Sarcoidosis, E.U, Patient, SAN, FDA, Fast track (FDA), Medicine, Pharmaceutical industry, Kyorin

SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD). This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.

Key Points: 
  • This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.
  • Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2).
  • Kyorin has the exclusive rights to develop and commercialize efzofitimod in Japan for all forms of ILD.
  • The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in the United States, Europe and Japan.

Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program

Retrieved on: 
Monday, August 3, 2020
Otorhinolaryngology, Otology, Hearing loss, Occupational safety and health, Neurotology, Sensorineural hearing loss, Kyorin, Nervous system, Medical specialties

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. (Kyorin) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.

Key Points: 
  • SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc.(Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with KYORIN Pharmaceutical Co., Ltd. (Kyorin) that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.
  • Otonomy is formulating the compound utilizing the companys proprietary technology to provide sustained drug exposure in the inner ear following a single local administration.
  • We are pleased to complete this license agreement that stems from a successful research collaboration with Kyorin focused on identifying a novel treatment for hearing loss, said David A. Weber, Ph.D., president and CEO of Otonomy.
  • We have demonstrated that this compound is active in preclinical models of cochlear hair cell regeneration, and has potential for the treatment of severe hearing loss.

Vectura Group plc: 2019 Preliminary Results 

Retrieved on: 
Tuesday, March 17, 2020
Pharmaceutical companies, Chippenham, Vectura Group, Novartis, Kyorin, Companies, Health

Commenting on the results, Will Downie, Chief Executive Officer of Vectura,said:

Key Points: 
  • Commenting on the results, Will Downie, Chief Executive Officer of Vectura,said:
    "I am pleased to report a solid set of results for 2019 which were ahead of expectations, underpinned by continued flutiform revenue growth.
  • Sharon Johnson joined Vectura as EVP Delivery Management, and Mark Bridgewater joined as Chief Commercial Officer
    Vectura will present its Preliminary Results via live webcast today from 9.30am to 10.30am GMT.
  • Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.
  • Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

aTyr Pharma Announces Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of ATYR1923 in Japan

Retrieved on: 
Monday, January 6, 2020
Kyorin

Kyorin will receive the exclusive right to develop and commercialize ATYR1923 in Japan for ILDs.

Key Points: 
  • Kyorin will receive the exclusive right to develop and commercialize ATYR1923 in Japan for ILDs.
  • We believe this collaboration further validates ATYR1923 and potentially accelerates development in other ILDs.
  • Per the terms of the agreement, Kyorin will be responsible for funding all research, development, regulatory, marketing and commercialization activities in Japan.
  • aTyr will supply all drug product for Japan, as well as support development activities as the global development leader for ATYR1923.

Hebrew University to Collaborate With KYORIN

Retrieved on: 
Thursday, December 27, 2018
Kyorin, Health, Hebrew University of Jerusalem, Medication, Technology transfer, Medical prescription, Medicine

JERUSALEM, Dec. 27, 2018 /PRNewswire/ -- Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem and KYORIN Pharmaceutical Co., Ltd. (Tokyo, Japan), a subsidiary of KYORIN Holdings, Inc., which is engaged in the development and commercialization of prescription drugs, announced today a strategic collaborationin the discovery of respiratory drug therapies.

Key Points: 
  • JERUSALEM, Dec. 27, 2018 /PRNewswire/ -- Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem and KYORIN Pharmaceutical Co., Ltd. (Tokyo, Japan), a subsidiary of KYORIN Holdings, Inc., which is engaged in the development and commercialization of prescription drugs, announced today a strategic collaborationin the discovery of respiratory drug therapies.
  • KYORIN focuses on R&D and commercialization of prescription drugs, and respiratory field is positioned as one of its franchises.
  • In the new partnership, KYORIN and Prof. Levi-Schaffer will collaborate and screen for new drugs based on her expertise of allergic inflammation.
  • For further information please visit www.kyorin-pharm.co.jp/en/
    Yissum is the technology transfer company of The Hebrew University of Jerusalem.